We investigated the relationship between platelet to lymphocyte ratio (PLR) and contrast-induced nephropathy (CIN) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI). We enrolled 5719 patients in 3 tertiary hospitals from January 2005 to December 2010. The PLR was calculated as the ratio of platelet to lymphocyte counts on admission. Serum creatinine level was measured before and within 72 hours after contrast medium administration. To evaluate the relation between PLR and CIN, the 5719 patients were divided into a CIN group and a non-CIN group. Contrast-induced nephropathy occurred in 252 (4.4%) patients. Patients in the CIN group had significantly higher PLR than those in the non-CIN group (173.8 [62.3] and 116.2 [51.7], respectively; P < .001). In logistic regression analysis, PLR was an independent predictor of CIN (odds ratio: 1.432, 95% confidence interval: 1.205-1.816, P ¼ .031), along with age, diabetes mellitus, creatinine, estimated glomerular filtration rate, and neutrophil to lymphocyte ratio. In conclusion, a higher PLR was an independent risk factor for the development of CIN in patients with STEMI undergoing pPCI.
Background
Contrast-induced nephropathy (CIN) refers to potentially reversible acute renal failure following contrast medium exposure during computed tomography 1 or interventional vascular angiography. 2 It is the third most common cause of hospital-acquired renal failure, after decreased renal perfusion and use of nephrotoxic medications. 3 Previous studies have reported that CIN may be associated with worse clinical outcomes including prolonged hospitalization, increased cost, risk of end-stage renal failure, repeat revascularization, and mortality. [4] [5] [6] [7] The pathogenesis of CIN is complex and multifactorial and the underlying biological mechanisms have not yet been fully understood. Several potential factors have been postulated, such as intrarenal vasoconstriction, reduced renal blood flow, medullary hypoxia, oxidative stress, inflammation, thrombosis, endothelial dysfunction, the generation of reactive oxygen species, and direct tubular epithelial cell injury by contrast media. 8, 9 Considering the prognosis, useful predictors of CIN are needed. The platelet to lymphocyte ratio (PLR) has been introduced as an indicator of several clinical conditions not only in malignancies 10 but also in other clinical settings such as peripheral arterial disease, 11 renal disease, 12 Graves' disease, 13 obstructive sleep apnea syndrome, 14 and metabolic syndrome. 15 Recent studies have extended these observations to cardiovascular diseases, especially ST-segment elevation myocardial infarction (STEMI). Current studies have reported that a higher PLR may be associated with the slow flow/no-reflow phenomenon, 16 higher synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) score, 17 impaired infarct-related artery patency, 18 stent restenosis, 19 and worsening in-hospital and long-term major adverse cardiovascular events in patients with STEMI. [20] [21] [22] [23] In China, STEMI accounts for almost 80% of acute myocardial infarction, and patients with STEMI undergoing primary percutaneous coronary intervention (pPCI) are at higher risk of CIN than those undergoing elective interventional procedures. 24 Therefore, the prophylactic measures to reduce the complication associated with STEMI are clinically relevant. Thus, we investigated the role of PLR in predicting CIN in patients with STEMI undergoing pPCI.
Methods

Study Population
This was a multicenter, retrospective analysis. Xuanwu Hospital, Beijing Friendship Hospital, and Beijing Luhe Hospital are the affiliated hospitals of Capital Medical University. We enrolled 7317 patients with STEMI in these tertiary hospitals from January 2005 to December 2010. ST-segment elevation myocardial infarction is a clinical syndrome defined by characteristic symptoms of myocardial ischemia in association with persistent electrocardiographic ST-segment elevation and subsequent release of biomarkers of myocardial necrosis. 25 Of the 7317 patients with STEMI enrolled during the study, we excluded 243 patients using thrombolytic drugs within the previous 24 hours and 167 patients with exposure to a contrast medium within the previous 10 days. We also excluded 1049 patients with chronic kidney disease (CKD); blood, hepatic, thyroid, autoimmune, or inflammatory diseases; or malignancy. We excluded patients who died before or during revascularization from the study. Patients who died after pPCI were also excluded since the clinical data were not complete during hospitalization. After excluding the 139 patients who died during the index hospitalization, 5719 patients made up the study population ( Figure 1 ).
Study Protocol
Blood samples were collected at the emergency department before any treatment, and serum creatinine level measurement was repeated at 72 hours after contrast medium administration. The hematological parameters were measured using an XE-5000 automated hematology analyzer (Sysmex, Kobe, Japan). The PLR and neutrophil to lymphocyte ratio (NLR) were obtained by dividing the absolute platelet or neutrophil counts by the absolute lymphocyte counts. According to the recommendations of clinical practice guidelines for the evaluation and management of CKD, the estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. 26 The eGFR ¼ 141 Â (minimum of standardized serum creatinine
À1.209 Â 0.993 age Â (1.018 if female) Â (1.159 if black), where k is 0.7 for females and 0.9 for males and a is À0.329 for females and À0.411 for males. Chronic kidney disease was defined as a decreased eGFR <60 mL/min/ 1.73 m 2 . Contrast-induced nephropathy was defined as !25% relative increase or !0.5 mg/dL absolute increase in serum creatinine level above baseline within 72 hours of contrast exposure, in the absence of an alternative explanation. 27 To evaluate the relation between PLR and CIN, the 5719 patients were divided into a CIN group and a non-CIN group. Demographic data, comorbidities (hypertension, diabetes mellitus, dyslipidemia, prior myocardial infarction, and cerebrovascular disease), and treatments were also recorded.
Coronary Angiography
On admission, all patients received chewable aspirin (300 mg), clopidogrel (600 mg), and atorvastatin (20 mg) if they were not already on a statin. A loading dose of statin before pPCI was not included in institutional protocol at the time period investigated in the present study. Coronary angiography and pPCI were performed according to standard clinical practice. Nonionic, iso-osmolar contrast medium (iodixanol, Visipaque 320 mg/100 mL; GE Healthcare, Cork, Ireland) was used to visualize the coronary arteries. Total contrast medium volume used during pPCI was recorded in all patients. All patients received standard weight-adjusted intravenous bolus unfractionated heparin (70-100 U/kg) before the coronary intervention. The dose of unfractionated heparin was reduced to 50 to 70 U/kg if patients were treated with glycoprotein IIb/IIIa inhibitor (tirofiban). The use of bare metal or drugeluting stents as well as tirofiban was left to the discretion of the interventional cardiologist. Procedural success was characterized as a residual stenosis of <20% without major complications (stent thrombosis, need for emergent coronary artery bypass graft, coronary dissection or rupture, and death). After intervention, all patients continued to take aspirin (100 mg/d) indefinitely and clopidogrel (75 mg/d) for at least 12 months. All patients received intravenous hydration with isotonic saline (0.9% sodium chloride at a rate of 1 or 0.5 mL/kg/h in cases of overt heart failure for 12 hours after the procedure).
Statistical Analysis
For baseline characteristics, the Kolmogorov-Smirnov test was used to test the normality of distribution. Quantitative variables with a normal distribution were specified as mean (standard deviation), variables with nonnormal distribution were shown as median (interquartile range), and categorical variables were shown as number and percentage values. For continuous variables with a normal distribution, the Student t test was used to compare groups, whereas the Mann-Whitney U test was used when the distribution was not normal. For categorical variables, the w 2 test or the Fisher exact test was used, as appropriate. To determine the independent predictors of CIN, parameters with a significance level of .1 or less on univariate analysis were included within the multivariate logistic regression model, and forward likelihood ratio was selected as the method to include parameters within the model. Receiver operating characteristic (ROC) curve analysis was performed in order to determine the best cutoff value of PLR and NLR, and the sensitivity and specificity at that point were obtained. Differences were considered significant at the 2-sided P < .05 level. All analyses were performed with SPSS statistical software version 17.0 (Chicago, Illinois).
Results
The study population consisted of 5719 patients with a mean age of 59.7 (11.2) years; 1305 (22.8%) patients were female; 252 (4.4%) patients developed CIN. Baseline demographic data and laboratory parameters are shown in Table 1 . The patients in the CIN group were significantly older, with a higher prevalence of hypertension and diabetes mellitus than those in the non-CIN group. In the CIN group, creatinine, blood urea nitrogen, serum glucose, high-sensitivity C-reactive protein (hsCRP), white blood cell, neutrophil, NLR, platelet, and PLR were higher, whereas eGFR, lymphocyte, and hemoglobin were lower compared with the non-CIN group.
The angiographic characteristics and medications during hospitalization are presented in Table 2 . The prevalence of multivessel disease and chronic total occlusion (CTO) was significantly greater in the CIN group compared with the non-CIN group. The total time of procedure, total amount of contrast medium, stent implantation, total length of stent, and stent diameter were not significantly different between groups. The rates of treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, oral hypoglycemic agents, and insulin were higher in patients who developed CIN. Treatments with dual antiplatelet therapy, tirofiban, statin, b-blocker, and Ca-blocker were similar in these 2 groups.
In a univariate model using PLR as a continuous variable, there was a significant positive association between PLR and the incidence of CIN. Age, hypertension, diabetes mellitus, creatinine, eGFR, serum glucose, hsCRP, NLR, hemoglobin, multivessel disease, and CTO were also associated with the development of CIN. Multivariate logistic regression analysis revealed that PLR (odds ratio [ (Table 3 ).
An ROC curve analysis was performed to determine the cutoff value of PLR and NLR to predict the development of CIN. The area under the curve (AUC) for PLR was 0.759 (95% CI: 0.717-0.801, P < .001), and a PLR cutoff of 127.5 or higher predicted CIN with a sensitivity of 76.8% and a specificity of 69.2% (Figure 2 ). The AUC for NLR was 0.724 (95% CI: 0.679-0.770, P < .001), and a NLR cutoff of 2.9 or higher predicted CIN with a sensitivity of 73.5% and a specificity of 70.4% (Figure 3 ).
Discussion
Contrast-induced nephropathy represents a significant adverse event of contrast medium administration, leading to worse clinical outcomes despite successful early coronary revascularization. The mechanisms of CIN remain poorly understood, although several mechanisms have been identified, revealing Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; BUN, blood urea nitrogen; CIN, contrast-induced nephropathy; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; RBC, red blood cell; T-Chol, total cholesterol; TG, triglyceride; WBC, white blood cell. Abbreviations: 95% CI, 95% confidence interval; eGFR, estimated glomerular filtration rate; hsCRP, high-sensitivity C-reactive protein; LDL-C, low density lipoprotein cholesterol; NLR, neutrophil to lymphocyte ratio; OR, odds ratio; PLR, platelet to lymphocyte ratio; T-Chol, total cholesterol; TG, triglyceride; WBC, white blood cell.
a Differences in bold show statistical difference at P < .1 for univariate analysis and P < .05 for multivariate analysis. a complex multifactorial physiopathology with a high interindividual variability of the nephrotoxic effect of contrast media. 28 Preexisting renal impairment, metabolic syndrome, congestive heart failure, peripheral artery disease (PAD), hypovolemia, older age, anemia, and the use of large contrast medium amounts may be risk factors for the development of CIN. 29 Emerging risk factors such as arterial stiffness, 30 oxidative stress, 31 elevated homocysteine, 32 hsCRP, 33 N-terminal pro-brain natriuretic peptide, 34 serum uric acid levels, 35 procalcitonin, 36 red cell distribution width, 37 and NLR, 38 as well as lower bilirubin concentrations, 39 have also been linked to CIN development. Because of the potential role of increased inflammatory activity and aggravated prothrombotic status in the development of CIN, mediators reflecting inflammation and thrombosis, such as PLR, might be a marker of CIN. Thus, we investigated the role of PLR in predicting CIN in patients with STEMI undergoing pPCI in this study.
In the present study, patients in the CIN group had significantly higher PLR than those in the non-CIN group, and higher PLR was an independent risk factor for the development of CIN in patients with STEMI undergoing pPCI. The results of the present study agree with the existing literature and further strengthen the predictive role of the PLR for CIN following catheter interventions. [40] [41] [42] The link between higher PLR and CIN is probably not a cause-effect relationship. It is more likely that both conditions may be 2 different manifestations of the same physiological impairments. Contrast-induced nephropathy is a specific type of cardiorenal syndrome. In addition to the toxicity of contrast media, CIN is also associated with hemodynamic effects of myocardial infarction. Abnormal hemodynamic states lead to a complex clinical situation mixing a decrease in renal blood flow, a high thrombogenic state, a burst of inflammation, oxidative stress, and neurohormonal activation. Both thrombocytosis and lymphocytopenia correlate with the degree of inflammation and thrombosis, and the PLR represents a novel marker incorporating both hematologic indices. 43 The advantage of the PLR could be that it reflects the condition of both inflammation and thrombosis pathways, and it may be more valuable than either platelet or lymphocyte counts alone. Since a complete blood count is easily available, the PLR may help clinicians to identify patients at high risk of CIN and decide whether postprocedural hydration is needed. Although the PLR only had a modest predictive accuracy for CIN in the present analysis, risk estimation for CIN should not be based solely on the PLR; all relevant predictors of CIN should be considered during clinical decision-making.
Besides the PLR, age, diabetes mellitus, creatinine, eGFR, and NLR were also the independent risk factors for the development of CIN in the present study. The risk of CIN is increased in elderly patients, which may be due to the presence of endothelial dysfunction and an exaggerated vasoconstrictive response to contrast media. 44 Diabetes mellitus is also an important risk factor and is synergistic with baseline kidney function. In 2 large registries of all-comer patients undergoing pPCI, diabetes mellitus was consistently identified as an independent predictor of CIN. 45, 46 Even impaired glucose tolerance has been reported to increase the risk of CIN in patients with CKD. 47 Preexisting CKD is probably the most important preprocedural risk factor for CIN. Although we excluded patients with CKD, creatinine and eGFR were also the independent risk factors for the development of CIN. The creatinine and eGFR may be the simple biochemical assessment of CIN, which can occur in patients without preexisting CKD. Like the PLR, the NLR has been investigated as a useful and reliable inflammatory prognostic marker for predicting CIN in a wide range of cardiovascular diseases, including STEMI, 38 non-STsegment elevation acute coronary syndrome 48 and PAD. 49 Our study corroborated and extended the results of earlier studies. In the present study, we have found significantly higher neutrophil counts and lower lymphocyte counts, resulting with a higher NLR. The higher NLR, representing overreaction of inflammatory state, may contribute to the development of CIN. Taken together, it may be advisable to consider early initiation of prophylactic measures to prevent CIN possibly by developing an index that includes these variables.
This study has some limitations. First, this was a retrospective analysis. Residual confounding factors might thus have affected the results, regardless of the adjusted analysis. Second, blood samples were obtained at the time of admission and we did not observe the serial changes in PLR concentration after pPCI. Third, several novel renal biomarkers, including neutrophil gelatinase-associated lipocalin, cystatin C, urinary Kim-1, and interleukin 18, were not measured. 50, 51 Further studies are needed to clarify the mechanisms underlying the relation between PLR and CIN.
In conclusion, a higher PLR was an independent risk factor for the development of CIN in patients with STEMI undergoing pPCI. Considering its clinical significance, the PLR may help identify high-risk candidates of CIN in these patients. Meanwhile, the power of the NLR was similar to that of the PLR in predicting CIN. Both ratios used the lymphocyte counts. Future studies need to establish which of these 2 markers is more appropriate for which category of patients. These studies should also consider whether the combined use of the PLR and NLR offers any advantages in terms of predicting long-term outcomes.
